Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Single-Dose, Single-Center, Open-Label, Three-Arm Study to Assess the Tolerability and Safety of Immune Globulin Subcutaneous (Human), 20% Solution With Recombinant Human Hyaluronidase (TAK-881) at Various Infusion Rates in Healthy Adult Subject

Next Previous
Trial Profile

A Phase 1, Single-Dose, Single-Center, Open-Label, Three-Arm Study to Assess the Tolerability and Safety of Immune Globulin Subcutaneous (Human), 20% Solution With Recombinant Human Hyaluronidase (TAK-881) at Various Infusion Rates in Healthy Adult Subject

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Allotransplant rejection; Alzheimer's disease; Ataxia; Chronic inflammatory demyelinating polyradiculoneuropathy; Chronic lymphocytic leukaemia; Guillain-Barre syndrome; HIV infections; Idiopathic thrombocytopenic purpura; Immunodeficiency disorders; Peripheral nervous system diseases
  • Focus Adverse reactions
  • Sponsors Takeda

Most Recent Events

  • 28 Apr 2022 Status changed from active, no longer recruiting to completed.
  • 09 Feb 2022 Status changed from recruiting to active, no longer recruiting.
  • 03 Dec 2021 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top